RGEN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

192.78M

+15.06%

0.444

+0.98%

191.51M

+13.21%

0.445

+14.17%

204.46M

+12.12%

0.501

+35.38%

Estimates Revision

The market is revising Upward the revenue expectations for Repligen Corporation (RGEN) for FY2025, with the revenue forecasts being adjusted by 0.92% over the past three months. During the same period, the stock price has changed by 34.10%.

Revenue Estimates for FY2025

Revise Upward

+0.92%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.91%

In Past 3 Month

Stock Price

Go Up

+34.10%

In Past 3 Month

15 Analyst Rating

Wall Street analysts forecast RGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RGEN is 183.36 USD with a low forecast of 135.00 USD and a high forecast of 220.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

4 Hold

0 Sell

Moderate Buy

Current: 160.580

Low

135.00

Averages

183.36

High

220.00

Current: 160.580

Low

135.00

Averages

183.36

High

220.00

Barclays

NULL

Overweight

maintain

$175 -> $200

2025-12-15

New

Reason

Barclays

Price Target

$175 -> $200

2025-12-15

New

maintain

NULL

Overweight

Reason

Barclays raised the firm's price target on Repligen to $200 from $175 and keeps an Overweight rating on the shares. The firm adjusted ratings and price targets in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the "most under-owned space in healthcare" creates a "great setup" for outperformance of the tools group in 2026, the analyst tells investors in a research note.

Wells Fargo

Overweight

maintain

$175 -> $190

2025-12-15

New

Reason

Wells Fargo

Price Target

$175 -> $190

2025-12-15

New

maintain

Overweight

Reason

Wells Fargo raised the firm's price target on Repligen to $190 from $175 and keeps an Overweight rating on the shares. With U.S. policy uncertainty lifting on Pharma and forward growth expectations already well-anchored with room for upside, the firm likes the setup for Tools.

Barclays

Overweight

maintain

$160 -> $175

2025-10-29

Reason

Barclays

Price Target

$160 -> $175

2025-10-29

maintain

Overweight

Reason

Barclays raised the firm's price target on Repligen to $175 from $160 and keeps an Overweight rating on the shares following the earnings report. The company's outlook downshift or next year is driven by a lower market growth outlook based on peer commentary, but there is potential upside, the analyst tells investors in a research note.

Canaccord

Hold

maintain

$150 -> $165

2025-10-29

Reason

Canaccord

Price Target

$150 -> $165

2025-10-29

maintain

Hold

Reason

Canaccord raised the firm's price target on Repligen to $165 from $150 and keeps a Hold rating on the shares. The firm raised estimates given the 3Q25 revenue beat and relatively improving biopharma outlook as the company reported 3Q25 results that were ahead of estimates while the company achieved revenue growth across all franchises led by Process Analytics.

HSBC

NULL -> Buy

initiated

$150

2025-10-01

Reason

HSBC

Price Target

$150

2025-10-01

initiated

NULL -> Buy

Reason

HSBC initiated coverage of Repligen with a Buy rating and $150 price target. While biotech funding and the regulatory environment are headwinds for the company, its volume leverage in a recovery is underappreciated, the analyst tells investors in a research note. The firm believes Repligen's portfolio in bioprocessing can drive double-digit revenue growth.

Evercore ISI

In Line

Outperform

upgrade

$130 -> $155

2025-09-22

Reason

Evercore ISI

Price Target

$130 -> $155

2025-09-22

upgrade

In Line

Outperform

Reason

Evercore ISI upgraded Repligen to Outperform from In Line with a price target of $155, up from $130. The firm believes the bioprocessing solutions end market is "relatively insulated" from macro headwinds and is now back now back to a normal high-single-digit growth cadence. Evercore believes Repligen's new business is delivering while its new modalities overhang "is seemingly removed."

Valuation Metrics

The current forward P/E ratio for Repligen Corp (RGEN.O) is 83.42, compared to its 5-year average forward P/E of 83.98. For a more detailed relative valuation and DCF analysis to assess Repligen Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

83.98

Current PE

83.42

Overvalued PE

103.72

Undervalued PE

64.23

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

56.69

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

71.08

Undervalued EV/EBITDA

42.31

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

13.99

Current PS

0.00

Overvalued PS

17.32

Undervalued PS

10.66

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 143.49% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 143.49% over the last month.

Sold

Bought

RGEN News & Events

Events Timeline

No data

News

6.0

10-29Benzinga

Canaccord Genuity Keeps Hold Rating on Repligen and Increases Price Target to $165

9.5

10-28NASDAQ.COM

Repligen (RGEN) Exceeds Expectations in Q3 Earnings and Revenue

6.5

10-28NASDAQ.COM

Analysts Predict 10% Growth Potential for PTL

People Also Watch

Frequently Asked Questions

What is Repligen Corp (RGEN) stock price today?

The current price of RGEN is 160.58 USD — it has increased 2.03 % in the last trading day.

What is Repligen Corp (RGEN)'s business?

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.

What is the price predicton of RGEN Stock?

What is Repligen Corp (RGEN)'s revenue for the last quarter?

Repligen Corp revenue for the last quarter amounts to 188.81M USD, increased 21.91 % YoY.

What is Repligen Corp (RGEN)'s earnings per share (EPS) for the last quarter?

Repligen Corp. EPS for the last quarter amounts to 0.26 USD, decreased -2700.00 % YoY.

What changes have occurred in the market's expectations for Repligen Corp (RGEN)'s fundamentals?

How many employees does Repligen Corp (RGEN). have?

Repligen Corp (RGEN) has 1778 emplpoyees as of December 16 2025.

What is Repligen Corp (RGEN) market cap?

Today RGEN has the market capitalization of 9.04B USD.